The Skinny on Weight Loss Drugs | Newton

As the obesity epidemic rages across the globe, new weight loss drugs have become so popular that some manufacturers are unable to meet patient demand. Dr. David Katz, founder and CEO of Diet ID, joins Double Take to discuss investment ramifications of these hotly demanded medications.

Presented by

Raphael J. Lewis

Raphael J. Lewis

Head of specialist research

Jack Encarnacao

Jack Encarnacao

Research analyst, investigative, Specialist Research team

Topics

Themes

More like this

Market Outlook: A Case of Déjà Vu?

We analyze how potentially higher-for-longer inflation could influence markets over the coming months.

April 24, 2024

Retake on Double Take: China Through an Investment Lens

As geopolitical tensions become a focal point, what should investors consider when investing in China?

March 28, 2024

Animal, Bird, Penguin

Parental Leave: Supporting Modern Parenthood

Modernizing parental leave could help drive a more gender-balanced economy.

February 28, 2024

See all insights

Explore topics